IL324467A - צורות פולימורפיות ופורמולציות של לריגליטזון - Google Patents
צורות פולימורפיות ופורמולציות של לריגליטזוןInfo
- Publication number
- IL324467A IL324467A IL324467A IL32446725A IL324467A IL 324467 A IL324467 A IL 324467A IL 324467 A IL324467 A IL 324467A IL 32446725 A IL32446725 A IL 32446725A IL 324467 A IL324467 A IL 324467A
- Authority
- IL
- Israel
- Prior art keywords
- leriglitazone
- crystalline
- disease
- degrees
- syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23382428 | 2023-05-09 | ||
| PCT/IB2024/054534 WO2024231881A2 (en) | 2023-05-09 | 2024-05-09 | Polymorphic forms and formulations of leriglitazone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL324467A true IL324467A (he) | 2026-01-01 |
Family
ID=86331222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL324467A IL324467A (he) | 2023-05-09 | 2024-05-09 | צורות פולימורפיות ופורמולציות של לריגליטזון |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4709476A2 (he) |
| AU (1) | AU2024268104A1 (he) |
| IL (1) | IL324467A (he) |
| MX (1) | MX2025013233A (he) |
| WO (1) | WO2024231881A2 (he) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8618847D0 (en) * | 1986-08-01 | 1986-09-10 | Smith Kline French Lab | Pharmaceutical formulations |
| CA2106967C (en) * | 1991-04-11 | 2003-12-09 | Takashi Sohda | Thiazolidinedione derivatives, production and use thereof |
| BR112014007366B1 (pt) * | 2011-10-05 | 2020-09-15 | Dupont Nutrition Usa, Inc | Processo para fabricar uma composição estabilizadora compreendendo extrusão em duas etapas, composição estabilizadora de celulose microcristalina e produto alimentício comestível e suspensão industrial compreendendo a mesma |
| EP3125888B1 (en) * | 2014-04-02 | 2018-05-23 | Minoryx Therapeutics S.L. | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| WO2016018860A1 (en) * | 2014-07-29 | 2016-02-04 | Fmc Corporation | Improved colloidal stabilizer |
| EP3548026B1 (en) | 2016-12-01 | 2021-01-20 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease |
| EP3559010B1 (en) | 2016-12-23 | 2022-06-08 | Minoryx Therapeutics S.L. | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
| EA202092954A1 (ru) * | 2018-06-06 | 2021-04-08 | Минорикс Терапьютикс С.Л. | Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей |
| BR112020024917A2 (pt) | 2018-06-06 | 2021-03-09 | Minoryx Therapeutics S.L. | Método de administrar uma quantidade terapeuticamente eficaz de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona |
| EP4142720A1 (en) * | 2020-04-30 | 2023-03-08 | Minoryx Therapeutics S.L. | Leriglitazone for treating lung inflammation and interstitial lung disease |
-
2024
- 2024-05-09 MX MX2025013233A patent/MX2025013233A/es unknown
- 2024-05-09 IL IL324467A patent/IL324467A/he unknown
- 2024-05-09 WO PCT/IB2024/054534 patent/WO2024231881A2/en not_active Ceased
- 2024-05-09 EP EP24726986.3A patent/EP4709476A2/en active Pending
- 2024-05-09 AU AU2024268104A patent/AU2024268104A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4709476A2 (en) | 2026-03-18 |
| AU2024268104A1 (en) | 2025-11-27 |
| WO2024231881A2 (en) | 2024-11-14 |
| WO2024231881A3 (en) | 2024-12-26 |
| MX2025013233A (es) | 2026-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7932273B2 (en) | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament | |
| KR101684053B1 (ko) | 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법 | |
| CZ2015504A3 (cs) | Krystalické formy obeticholové kyseliny | |
| US20240417390A1 (en) | Hydrogen sulfate salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same | |
| TW420681B (en) | Carbapenem-3-carboxylic acid ester derivatives | |
| EP3613733A1 (en) | Novel crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin-2-yl)-1h-pyrazol-5-ol hydrochloride | |
| TW201920163A (zh) | (2s)‐2‐[[(z)‐[1‐(2‐胺基‐4‐噻唑基)‐2‐[[(3s)‐2,2‐二甲基‐4‐側氧基‐1‐(磺氧)‐3‐吖丁啶基]胺基]‐2‐氧亞乙基]胺基]氧基]‐3‐[4‐[亞胺基[(3r)‐3-哌啶基胺基]甲基]苯氧基]-丙酸之晶型 | |
| US20250382286A1 (en) | Co-crystal of aficamten, and preparation method therefor and use thereof | |
| US11124517B2 (en) | Crystal form of Baricitinib and preparation method thereof | |
| IL324467A (he) | צורות פולימורפיות ופורמולציות של לריגליטזון | |
| US11117868B2 (en) | Edaravone salt | |
| US11014888B2 (en) | Crystalline form of alkynyl pyridine prolyl hydroxylase inhibitor and method for preparing same | |
| US10479810B2 (en) | Crystal form of tenofovir alafenamide salt, preparation method and use thereof | |
| US20200199070A1 (en) | Crystalline Eravacycline Bis-Hydrochloride | |
| US20240059661A1 (en) | Solid state forms of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof | |
| KR101741403B1 (ko) | 안정한 결정형 보르테조밉 | |
| US20190263760A1 (en) | Crystalline Forms of Lesinurad | |
| IL312512A (he) | אגוניסט לקולטן s1p1, מלחו, צורתו הגבישית, והרכב רוקחי | |
| US10995083B2 (en) | Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4H-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition | |
| US12180242B2 (en) | Pharmaceutical crystal of contezolid acefosamil, preparation method therefor, and uses thereof | |
| CN113603673B (zh) | 一种盐酸度洛西汀的晶型、其制备方法及其应用 | |
| US20250026777A1 (en) | Cocrystals of nicotinamide riboside salts, crystalline forms, methods of preparation, and applications thereof | |
| US20220372006A1 (en) | Solid state forms of pemafibrate | |
| CN111747899B (zh) | 嘧菌酯通道型溶剂化物、共晶及其制备方法 | |
| WO2023219106A1 (ja) | 2-メチル-2-チアゾリンの塩 |